We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

118 hedge funds and large institutions have $91.5M invested in Sanofi Contingent Value Rights in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 34 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more capital invested

Capital invested by funds: $59.7M → $91.5M (+$31.8M)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more funds holding

Funds holding: 118 → 118 (0)

62% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 34

Holders
118
Holders Change
–
Holders Change %
0%
% of All Funds
3.15%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
15
Increased
13
Reduced
34
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OAM
Oxford Asset Management
United Kingdom
+$2.4M
2
LCM
Lonestar Capital Management
California
+$888K
3
CPM
Chesapeake Partners Management
Maryland
+$332K
4
SAM
Silverback Asset Management
North Carolina
+$69.5K
5
CCA
Catalyst Capital Advisors
New York
+$46.6K

Top Sellers

Rank Fund Capital Flow
1
GCM
Gruss Capital Management
New York
-$3.02M
2
NM
Newtyn Management
New York
-$822K
3
BPGAM
BTG Pactual Global Asset Management
Bermuda
-$372K
4
MCM
Mason Capital Management
New York
-$278K
5
WA
Whitebox Advisors
Minnesota
-$250K
Name Holding Trade Value Shares
Change 		Change in
Stake
DBG
51
De Burlo Group
Massachusetts
$31K – – –
Morgan Stanley
52
Morgan Stanley
New York
$28K -$14.9K -21,819 -38%
CHAM
53
Clear Harbor Asset Management
Connecticut
$27K – – –
WHI
54
William Harris Investors
Illinois
$26K – – –
OC
55
Oppenheimer & Co
New York
$23K – – –
RP
56
Reinhart Partners
Wisconsin
$16K – – –
Citadel Advisors
57
Citadel Advisors
Florida
$14K -$8.25K -12,079 -40%
BIA
58
Biondo Investment Advisors
Pennsylvania
$13K -$85 -125 -0.7%
HK
59
Horizon Kinetics
New York
$13K – – –
MC
60
Moors & Cabot
Massachusetts
$13K – – –
PNC Financial Services Group
61
PNC Financial Services Group
Pennsylvania
$11K -$523 -766 -5%
RL
62
Ruffer LLP
United Kingdom
$11K – – –
AG
63
Aperio Group
California
$10K -$98 -143 -1%
BlackRock
64
BlackRock
New York
$9K – – –
WS
65
Wedbush Securities
California
$9K +$7.54K +11,044 New
DA
66
Dillon & Associates
Michigan
$8K – – –
KAM
67
Kassirer Asset Management
Ontario, Canada
$8K +$6.83K +10,000 New
Deutsche Bank
68
Deutsche Bank
Germany
$6K – – –
BNP Paribas Financial Markets
69
BNP Paribas Financial Markets
France
$5.13K – – –
Bank of Montreal
70
Bank of Montreal
Ontario, Canada
$5K – – –
UOC
71
University of Chicago
Illinois
$4K +$7.04K +10,303 New
CTC
72
Central Trust Company
Missouri
$3K -$1.57K -2,300 -35%
US Bancorp
73
US Bancorp
Minnesota
$3K – – –
HF
74
Hoxton Financial
West Virginia
$2K – – –
NEAM
75
New England Asset Management
Connecticut
$2K – – –
1 2
3
4 5

GCVRZ Hedge Fund Activity: Q4 2014 in Review

118 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2014, worth a combined $91.5M — up 53% from $59.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GCVRZ positions and 14 closed out — a net gain of 1 holder — while 13 added to existing stakes and 34 trimmed.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.4M. The largest seller was Gruss Capital Management, cutting an estimated $3.02M.

  • 118 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $91.5M of Sanofi Contingent Value Rights stock for Q4 2014, up 53% quarter-over-quarter.
  • 15 funds opened new Sanofi Contingent Value Rights positions in Q4 2014 and 14 closed out, a net change of +1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2014 was Oxford Asset Management, an estimated $2.4M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2014 was Gruss Capital Management, an estimated $3.02M sold.

Based on aggregated 13F filings for Q4 2014.